Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that it will present two poster presentations covering an update from its pivotal Phase 2/3 GAIN Trial of atuzaginstat, in addition to new data demonstrating the upstream role that P. gingivalis plays in key pathology of Alzheimer’s disease, at the Alzheimer's Association International Conference® 2021 (AAIC®) taking place July 26-30, 2021, in Denver, Colorado, as well as virtually.
AAIC 2021 Poster Presentation Details
Topic: An update and baseline data from the Phase 2/3 GAIN trial of COR388 (atuzaginstat), a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease
Presenter: Michael Detke, MD, PhD, Cortexyme’s Chief Medical Officer
Authors: Michael Detke, MD, PhD1, Shirin Kapur, PhD1, Marwan Sabbagh, MD2, Mark Ryder, DMD3, Ira Goodman, MD4, Debasish Raha, PhD1, Florian Ermini, PhD1, Mai Nguyen, PhD1, Ursula Haditsch, PhD1, Joanna Bolger1, Dave Hennings, PhD1, Kim Perry, PhD5, Kelly Ritch, MS6, Casey Lynch1, Hatice Hasturk, DDS, PhD6, Leslie J. Holsinger, PhD1, Stephen Dominy, MD1
Topic: Examining phospho-tau217 in neuron cultures and CVN mice infected with Porphyromonas gingivalis and effects of gingipain inhibition
Presenter: Florian Ermini, PhD, Cortexyme’s Associate Director, In Vivo Pharmacology and Translational Biology
Authors1: Florian Ermini, PhD, Ursula Haditsch, PhD, Aurora Martinez-Horta, Leo Rodriguez, Sean Broce, Mai Nguyen, PhD, Debasish Raha, PhD, Shirin Kapur, PhD, Leslie Holsinger, PhD, Casey Lynch, Stephen Dominy, MD
Cortexyme’s posters will be available on Monday, July 26, 2021, beginning at 10:00 a.m. Eastern Time (8:00 a.m. Mountain Time) via AAIC 2021’s virtual conference experience here, as well as on the company’s website under the Science section accessible here.
https://finance.yahoo.com/news/cortexyme-present-data-aaic-2021-120000134.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.